ALOT vs HIT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AstroNova (ALOT) exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health. While the stock appears cheap on a Price-to-Sales (0.60) and Price-to-Book (1.16) basis, this is offset by negative profit margins (-11.20%) and declining year-over-year revenue growth (-3.10%). Recent price momentum is starkly disconnected from the underlying deterministic health scores and a bearish technical trend. The company is currently a value trap where low valuation metrics are justified by deteriorating operational efficiency.
HIT presents a high-risk profile characterized by a Piotroski F-Score of 4/9 (Stable) but severe technical deterioration. While the company exhibits strong revenue growth (53.10%) and an exceptionally clean balance sheet (Debt/Equity 0.01), it is trading at a massive premium to its Graham Number ($0.37) and Intrinsic Value ($0.14). The stock is currently in a freefall with a 0/100 technical trend and a 60.8% decline over the last six months, coupled with a poor earnings track record of 0/4 beats.
Compare Another Pair
Related Comparisons
ALOT vs HIT: Head-to-Head Comparison
This page compares AstroNova, Inc. (ALOT) and Health In Tech, Inc. (HIT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.